Finerenone Use in Patients with Heart Failure with Reduced Ejection Fraction

SUMMARY

Phase II randomized controlled studies

The phase II, randomized, double-blind ARTS1 study investigated safety and tolerability of oral finerenone in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and mild or moderate chronic kidney disease (CKD). Most patients (95.4% in Part A and 81.6% in Part B) were in New York Heart Association (NYHA) class II and the remaining patients were in class III.

In Part A (n=65), patients with HFrEF and mild CKD received oral finerenone (2.5-10 once daily [OD]) or placebo for 4 weeks. The effects on serum potassium concentration, estimated glomerular filtration rate (eGFR), and albuminuria were assessed. In Part A, most treatment emergent adverse events (TEAEs) were mild and unrelated to the study drug. Serious TEAEs occurred in 2 of 65 patients (3.1%). One case of hyperkalaemia was reported in the finerenone 10 mg OD group, but treatment was not discontinued and potassium levels returned to normal and remained in the normal range throughout the study.

Once the safety and tolerability of finerenone was confirmed in Part A, part B was initiated. In Part B (n=392), patients with HFrEF and moderate CKD received oral finerenone (2.5, 5, or 10 mg OD or 5 mg twice daily [BID]) placebo, or open-label spironolactone for 4 weeks. In part B, the primary endpoint was the mean change in serum potassium concentration, from baseline to Visit 6 (day 22 ± 2) and Visit 7 (day 29 ± 2).

  • Finerenone was associated with significantly smaller mean increases in serum potassium concentration between baseline and Visit 6 and Visit 7 than spironolactone (0.04-0.30 and 0.45 mmol/L, respectively, P < 0.0001 for 2.5, 5, and 10 mg OD and P = 0.0107 for 5 mg BID) and lower incidences of hyperkalemia (5.3 vs. 12.7%, respectively, P = 0.048) and worsening renal function.
  • Finerenone decreased two biomarkers of hemodynamic stress; B-type natriuretic peptide (BNP), amino-terminal proBNP, as well as albuminuria, at least as much as spironolactone. Adverse events related to finerenone were infrequent and mostly mild.

This page is intended for US healthcare professionals and may contain information outside of the approved prescribing information. It is provided in response to an unsolicited request. It is not intended as an endorsement of any usage not contained in the Prescribing Information. This response should be reviewed together with the current full Prescribing Information (including Boxed Warning) and Medical Safety Summary. These materials contain the approved indications, contraindications, warnings and precautions, adverse reactions, and other important safety information for Kerendia® (Finerenone).

Kerendia is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) indicated to: reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with Type 2 diabetes mellitus (T2DM); reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained eGFR decline and end-stage kidney disease in adults with CKD associated with Type 1 diabetes mellitus (T1DM); reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%.

 

The phase IIb, randomized, double-blind ARTS-HF2 study compared 5 different doses of finerenone OD (2.5, 5, 7.5, 10, or 15 mg uptitrated to 5, 10, 15, 20, or 20 mg, respectively, on Day 30) with eplerenone in 1066 patients with worsening chronic HFrEF NYHA class II–IV and CKD and/or diabetes mellitus (DM) for 90 days:

  • In both the finerenone and eplerenone groups, a similar proportion of patients demonstrated a drop in NT-proBNP levels >30% from baseline to Day 90. (P = 0.42– 0.88).
  • Moreover, the composite key exploratory clinical endpoint (death from any cause, cardiovascular [CV] hospitalizations, or emergency presentation for worsening HF) at Day 90 occurred numerically less frequently with finerenone compared with eplerenone, except in the 2.5→5 mg group; reaching nominal statistical significance in the 10→20 mg group (hazard ratio [HR] 0.56, 95% Confidence Interval [CI] 0.35-0.90; nominal P = 0.02).

     

Retrospective/Prospective Studies

  • A retrospective propensity score-matched study using the TriNetX database by Wu et al (2025)3 compared finerenone with steroidal mineralocorticoid receptor antagonists (MRAs,spironolactone/eplerenone) in 3238 patients (1619 per group) diagnosed with HF from January 2021 to February 2025. Finerenone was associated with a lower risk of the composite endpoint of all-cause mortality, all-cause hospitalization, and worsening HF compared with steroidal MRAs (HR 0.79, 95% CI 0.70-0.90; P < 0.001). Subgroup analyses showed consistent benefits across HF phenotypes, with reduced risks of primary and secondary outcomes in both HFrEF and HF with preserved ejection fraction (HFpEF) populations. No statistically significant differences were observed between finerenone and the steroidal MRA group in terms of hyperkalemia, acute kidney injury, or gynecomastia.
  • A retrospective cohort study by Odukudu et al (2026)4 compared year outcomes in patients with HFrEF treated with spironolactone (n=508 661) or finerenone (n=963) over a 5-year period using the TriNetX database. The index event was the first documentation of systolic HF with initiation of MRA. After propensity score matching, 960 patients in each cohort were well-balanced for demographics, comorbidities, and CV medications. Over a mean follow-up of approximately 1 year, finerenone demonstrated significantly better outcomes compared to spironolactone across multiple endpoints: all-cause mortality (10.5% vs. 15.5%, P = 0.001; HR 1.488, CI 1.154-1.919), acute myocardial infarction (14.3% vs. 19.1%, P = 0.005; HR 1.392, CI 1.115-1.737), rehospitalization (32.2% vs. 37.4%, P = 0.017; HR 1.231, CI 1.057-1.433), acute HF exacerbation (24.8% vs. 40.0%, P < 0.001; HR 1.892, CI 1.609-2.225) and cardiogenic shock (3.1% vs 6.0%, P = 0.002, HR 1.986, CI 1.276-3.089). Stroke rates showed a non-significant trend favoring finerenone (2.7% vs 4.1%, P = 0.127).
  • A prospective observational study by Zhao et al (2026)5 in 67 Chinese patients with postmyocardial infarction HF included patients with HFpEF (46.27%), HF with mildly reduced ejection fraction (HFmrEF,40.30%), and HFrEF (13.43%). Adding finerenone to guideline directed medical therapy for 3 months was associated with significant improvements in cardiac structure and function, a reduction in urinary albumin-to-creatinine ratio, and better functional capacity and quality of life. Results were not analyzed specifically for the HFrEF subpopulation.


 

Ongoing study

FINALITY-HF is an ongoing international, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of finerenone in patients with HFrEF who are intolerant or ineligible to receive treatment with steroidal MRA. Primary outcomes are time to first occurrence of CV death or HF event, number of serious adverse events, and number of adverse events leading to discontinuation of finerenone. The study plans to enroll 2600 patients with a study duration of up to 30 months6.

 

LITERATURE SEARCH

A literature search of Embase® , PubMed® , and/or other resources, including internal/external databases, was conducted pertaining to this topic on August 17, 2026.

 

References

All references were accessed on the literature search date.

  1. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–63. PMID: 23713082 https://www.ncbi.nlm.nih.gov/pubmed/23713082
  2. Filippatos G, Anker SD, Bohm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105–14. PMID: 27130705 https://www.ncbi.nlm.nih.gov/pubmed/27130705
  3. Wu JY, Tseng KJ, Lin YM. Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. J Am Heart Assoc. 2025:e043373. PMID: 41128135 https://www.ncbi.nlm.nih.gov/pubmed/41128135
  4. Odukudu G-dO, Dele D, Ajibade A, et al. 26-A-19412-ACC CLINICAL OUTCOMES AMONG HFREF PATIENTS ON SPIRONOLACTONE VS. FINERENONE: A REALWORLD PROPENSITY-MATCHED ANALYSIS. JACC. 2026;87(13_Supplement):A744–A745. PMID: https://www.jacc.org/doi/abs/10.1016/j.jacc.2026.02.1930
  5. Zhao D, Xia J, Yang Z, Yong Y, Wang L, Liu J. Finerenone combined with guidelinedirected medical therapy in patients with post-myocardial infarction heart failure: a realworld study. Front Pharmacol. 2026;17:1754115. PMID: 42292799 https://www.ncbi.nlm.nih.gov/pubmed/42292799
  6. NCT06033950_A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF). Updated March 11, 2025, Accessed via https://www.clinicaltrials.gov/study/NCT06033950